MTOR and dry age related macular degeneration: Inhibiting mTOR in the RPE with either a chemical inhibitor (TORIN1) or a biological regulator (βA3/A1‐crystallin) rescued the observed molecular and phenotypic changes, suggesting that targeting the mTOR complex represents a potential therapeutic strategy for dry AMD patients.